Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:12 AM
Ignite Modification Date:
2025-12-25 @ 1:12 AM
NCT ID:
NCT04072393
Eligibility Criteria:
Inclusion Criteria:
* Pathologically confirmed or radiographically diagnosed non-small cell lung cancer, small cell lung cancer, esophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, sarcoma, thymoma, or left-sided breast cancer.
* Planning to receive neo-adjuvant, adjuvant, or definitive radiation therapy to the thorax with curative intent.
* Willing to participate in home-based cardiac rehabilitation program and be monitored remotely via smart phone application
* Possess a smart phone or tablet capable of supporting teleHeart application
* Willing and eligible to co-enroll in the Cardiovascular Toxicity in Cancer and Improvement in Recovery (SURVIVE) Registry Study (HRPO# 201801031).
* At least 18 years of age.
* ECOG performance status ≤ 2
* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
* Presence of distant metastatic disease (except patients with lymphoma).
* Life expectancy less than 6 months
* Patient lives in skilled nursing facility, chronic care facility, nursing home, or palliative care or hospice facility
* Unable to walk
* Presence of significant cancer disease burden that would make patient unlikely to tolerate cardiac rehabilitation (CR)
* Diagnosis of primary cervical esophageal cancer.
* Presence of unstable angina.
* Recipient of heart transplant.
* Patient on cardiac transplant list or has a ventricular assist device
* Patient's baseline weight \> 300 lbs (due to weight limitations of the scale and bioelectrical impedance device)
* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
* Other medical comorbidities that make the patient unable to participate in the CR program or other assessments involved with this study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04072393
Study Brief:
Protocol Section:
NCT04072393